Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
2Seventy Bio Inc (TSVT)
2Seventy Bio Inc (TSVT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 285,525
  • Shares Outstanding, K 50,625
  • Annual Sales, $ 91,500 K
  • Annual Income, $ -254,150 K
  • 60-Month Beta 1.84
  • Price/Sales 1.78
  • Price/Cash Flow N/A
  • Price/Book 0.86
Trade TSVT with:

Options Overview Details

View History
  • Implied Volatility 175.90% ( +20.08%)
  • Historical Volatility 104.69%
  • IV Percentile 92%
  • IV Rank 56.88%
  • IV High 295.31% on 11/22/23
  • IV Low 18.37% on 10/19/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 25
  • Volume Avg (30-Day) 125
  • Put/Call OI Ratio 1.14
  • Today's Open Interest 5,633
  • Open Int (30-Day) 5,375

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -1.22
  • Number of Estimates 3
  • High Estimate -0.93
  • Low Estimate -1.37
  • Prior Year -0.60
  • Growth Rate Est. (year over year) -103.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.86 +16.05%
on 02/05/24
6.40 -11.88%
on 02/20/24
+0.45 (+8.67%)
since 02/01/24
3-Month
1.92 +193.75%
on 12/04/23
6.40 -11.88%
on 02/20/24
+3.70 (+190.72%)
since 12/01/23
52-Week
1.53 +267.43%
on 11/22/23
12.69 -55.56%
on 06/09/23
-5.37 (-48.77%)
since 03/01/23

Most Recent Stories

More News
2 Growth Stocks That Could Rocket Higher Before the End of 2023

Potential approvals of new medicines expected soon could push these stocks through the roof.

PFE : 26.59 (+0.11%)
ALNY : 152.61 (+1.01%)
TSVT : 5.64 (+8.46%)
BMY : 50.89 (+0.28%)
2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates

2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of 9.24% and 115.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

TSVT : 5.64 (+8.46%)
SEER : 1.8200 (unch)
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress

2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy Company, today reported financial results and recent highlights for the first quarter ended March 31, 2023.

TSVT : 5.64 (+8.46%)
2seventy bio to Present New Preclinical and Clinical Data from Broad Portfolio of Investigational Cell Therapies at the ASGCT 26th Annual Meeting

2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced the presentation of five abstracts, including one late-breaking oral presentation, at this year’s American...

TSVT : 5.64 (+8.46%)
Analysts Estimate Merus N.V. (MRUS) to Report a Decline in Earnings: What to Look Out for

Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MRUS : 51.82 (+6.89%)
TSVT : 5.64 (+8.46%)
2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program

2seventy bio, Inc. (Nasdaq: TSVT) a leading immuno-oncology cell therapy company, today announced that it has achieved a preclinical $15 million milestone as part of the joint research and development...

TSVT : 5.64 (+8.46%)
2seventy bio to Report First Quarter 2023 Financial Results on May 3, 2023

2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, will announce its first quarter 2023 financial results on Wednesday, May 3, 2023. 2seventy bio will host a conference...

TSVT : 5.64 (+8.46%)
Bristol Myers Squibb Reports First Quarter Financial Results for 2023

Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2023, which reflect robust in-line and new product portfolio growth, strong commercial execution and continued advancement...

BMY : 50.89 (+0.28%)
TSVT : 5.64 (+8.46%)
GSK Gears Up to Report Q1 Earnings: What's in the Cards?

We expect GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Bexsero, Shingrix and Juluca to drive first-quarter sales.

GSK : 42.03 (+0.31%)
AMRN : 1.0600 (-0.93%)
CRSP : 83.75 (-0.56%)
TSVT : 5.64 (+8.46%)
Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?

On Vertex's (VRTX) Q1 earnings call, investors will likely focus on the sales performance of its cystic fibrosis medicines and development updates of its non-CF pipeline.

VRTX : 432.76 (+2.86%)
AMRN : 1.0600 (-0.93%)
CRSP : 83.75 (-0.56%)
TSVT : 5.64 (+8.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

2seventy bio Inc. is a cell and gene therapy company. It focuses on the research, development, and commercialization of treatments for cancer. 2seventy bio Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 6.27
2nd Resistance Point 5.99
1st Resistance Point 5.81
Last Price 5.64
1st Support Level 5.35
2nd Support Level 5.07
3rd Support Level 4.89

See More

52-Week High 12.69
Fibonacci 61.8% 8.43
Fibonacci 50% 7.11
Fibonacci 38.2% 5.80
Last Price 5.64
52-Week Low 1.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar